Figure 2.

Key strategies of AAV vector-based cancer therapy, applied in preclinical studies so far, are summarized according to the hallmarks of cancer they are addressing. While the interest in anti-angiogenic treatment strategies, which have been a main focus of AAV vector-mediated cancer gene therapy during the last two decades is decreasing, according to the number of newly published papers, the interest and efforts to use AAV vectors for cancer immunotherapy is steadily increasing. Both the development of novel AAV vector-based vaccine strategies and AAV vector-based ex vivo and potentially in vivo modification of immune cells represent promising new avenues for future developments.